The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The list price for Ozempic and Mounjaro each run more than $1,000 ... suppliers haven't been able to meet demand almost since the FDA approved Ozempic for diabetes in 2017. Last week, the FDA ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed lawsuits against sellers falsely claiming to sell FDA-approved versions of the drug.

FDA approval for Zepbound to treat sleep apnea ... they mimic a hormone in the body known as glucagon-like peptide 1. Mounjaro and Zepbound are versions of a drug called tirzepatide.

The FDA has not yet approved tirzepatide for weight loss or the management of type 2 diabetes. To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Even though Mounjarno is sometimes used for weight loss, the FDA has only approved it for diabetes. For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the same ...